Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.323 SEK | -2.42% | +25.68% | -96.77% |
22/05 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
16/05 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
End-of-day quotes
Sector Other Biotechnology & Medical Research
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
4.74Cr | - | |||||
5.93TCr | - | |||||
4.02TCr | ||||||
3.99TCr | ||||||
2.86TCr | ||||||
2.73TCr |